<p>Olema Pharmaceuticals（纳斯达克代码：OLMA - 获取免费报告）在周五发布的报告中，摩根大通将其目标价格从 30.00 美元下调至 28.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “增持”。</p>
<p>获取 <strong>Olema Pharmaceuticals</strong> 的提醒：</p>
<p>其他几家券商也对 OLMA 发布了报告。HC Wainwright 在 3 月 19 日的研究报告中重申了对 Olema Pharmaceuticals 的 “买入” 评级，并设定了 30.00 美元的目标价格。Oppenheimer 在 3 月 19 日的报告中重申了 “跑赢大盘” 的评级，并将 Olema Pharmaceuticals 的目标价格设定为 25.00 美元（之前为 30.00 美元）。</p>
<p><strong>查看我们最新的 Olema Pharmaceuticals 股票报告</strong></p>
<h2>Olema Pharmaceuticals 价格表现</h2>
<p>周五，OLMA 股票开盘价为 4.20 美元。该股票的市值为 2.87 亿美元，市盈率为-1.92，贝塔系数为 2.11。该公司的 50 日简单移动平均线为 5.02 美元，200 日简单移动平均线为 8.14 美元。Olema Pharmaceuticals 的年内最低价为 3.93 美元，最高价为 16.62 美元。</p>
<p>Olema Pharmaceuticals（纳斯达克代码：OLMA - 获取免费报告）最近在 3 月 18 日发布了季度财报。该公司报告季度每股收益为（0.51 美元），超出分析师一致预期的（0.63 美元）0.12 美元。整体来看，研究分析师预计 Olema Pharmaceuticals 在当前年度的每股收益将为-2.33 美元。</p>
<h2>Olema Pharmaceuticals 内部活动</h2>
<p>在相关消息中，主要股东 Bain Capital Life Sciences Inv 于 1 月 8 日购买了 30 万股该公司的股票。该股票的平均购买价格为每股 5.76 美元，总交易额为 1,728,000.00 美元。购买后，该内部人士现在直接持有 780 万股公司股票，估值约为 44,928,000 美元。此交易代表其持股比例增加了 4.00%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站访问。19.40% 的股票由内部人士持有。</p>
<h2>对 Olema Pharmaceuticals 的对冲基金看法</h2>
<p>机构投资者和对冲基金最近买卖了该公司的股票。Intech Investment Management LLC 在第三季度购买了 Olema Pharmaceuticals 的新头寸，价值为 163,000 美元。Charles Schwab Investment Management Inc.在第三季度将其在 Olema Pharmaceuticals 的持股比例提高了 168.5%。Charles Schwab Investment Management Inc.现在持有该公司 330,761 股股票，价值为 3,949,000 美元，此前在该期间内又增持了 207,565 股。Dynamic Technology Lab Private Ltd 在第三季度购买了 Olema Pharmaceuticals 的新股份，价值约为 238,000 美元。Portland Investment Counsel Inc.在第三季度购买了 Olema Pharmaceuticals 的新股份，价值约为 143,000 美元。最后，Ikarian Capital LLC 在第三季度购买了 Olema Pharmaceuticals 的新头寸，价值约为 1,098,000 美元。91.78% 的股票由机构投资者持有。</p>
<h2>Olema Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Olema Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于女性癌症治疗的发现、开发和商业化。其主要产品候选药物为 OP-1250，一种雌激素受体（ER）拮抗剂和选择性 ER 降解剂，目前正在进行针对复发性、局部晚期或转移性雌激素受体阳性、HER2 阴性乳腺癌的三期临床试验；同时 OP-1250 与 CDK4/6 抑制剂 palbociclib、ribociclib 和 alpelisib 联合进行一期/二期临床试验，治疗复发性、局部晚期或转移性雌激素受体阳性、HER2 阴性乳腺癌，并开发 OPERA-01 用于 ER+/HER2-晚期或转移性乳腺癌的治疗。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Olema Pharmaceuticals</li>
<li>2025 年可能大幅上涨的两只 CRM 平台股票</li>
<li>Ibotta 股票：为何回购看起来像是一个看涨的赌注</li>
<li>突破股票：它们是什么以及如何识别它们</li>
<li>Joby Aviation 股票：分析师信心与聪明资金一致</li>
<li>如何投资小型股</li>
<li>3 只接近 52 周高点的动量股，值得关注以获取更多增长</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Olema Pharmaceuticals 吗？</h2>
<p>在考虑 Olema Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Olema Pharmaceuticals 并不在名单上。</p>
<p>虽然 Olema Pharmaceuticals 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

摩根大通

OLMA

<p>摩根大通已将 Olema Pharmaceuticals（纳斯达克代码：OLMA）的目标股价从 30.00 美元下调至 28.00 美元，同时维持 “增持” 评级。其他券商也给出了不同的评级，HC Wainwright 设定了 30.00 美元的目标，而 Oppenheimer 则将其下调至 25.00 美元。Olema 的股票开盘价为 4.20 美元，市值为 2.87 亿美元。该公司报告的季度每股收益为（0.51 美元），超出预期。内部交易方面，贝恩资本生命科学购买了 300,000 股，增持了 4% 的股份</p>

<p>Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) had its price objective reduced by JPMorgan Chase &amp; Co. from $30.00 to $28.00 in a report released on Friday,Benzinga reports. The firm currently has an &#34;overweight&#34; rating on the stock.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals（纳斯达克代码：OLMA - 获取免费报告）在周五发布的报告中，摩根大通将其目标价格从 30.00 美元下调至 28.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “增持”。</p>
</div><p>Get <strong>Olema Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Olema Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several other brokerages have also issued reports on OLMA. HC Wainwright reissued a &#34;buy&#34; rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th. Oppenheimer restated an &#34;outperform&#34; rating and set a $25.00 price objective (down previously from $30.00) on shares of Olema Pharmaceuticals in a report on Wednesday, March 19th.</p>
<div class="lb-trans"><p>其他几家券商也对 OLMA 发布了报告。HC Wainwright 在 3 月 19 日的研究报告中重申了对 Olema Pharmaceuticals 的 “买入” 评级，并设定了 30.00 美元的目标价格。Oppenheimer 在 3 月 19 日的报告中重申了 “跑赢大盘” 的评级，并将 Olema Pharmaceuticals 的目标价格设定为 25.00 美元（之前为 30.00 美元）。</p>
</div><p><strong>View Our Latest Stock Report on Olema Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Olema Pharmaceuticals 股票报告</strong></p>
</div><h2>Olema Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 价格表现</h2>
</div><p>Shares of OLMA stock opened at $4.20 on Friday. The stock has a market capitalization of $287.00 million, a PE ratio of -1.92 and a beta of 2.11. The business's 50 day simple moving average is $5.02 and its 200 day simple moving average is $8.14. Olema Pharmaceuticals has a one year low of $3.93 and a one year high of $16.62.</p>
<div class="lb-trans"><p>周五，OLMA 股票开盘价为 4.20 美元。该股票的市值为 2.87 亿美元，市盈率为-1.92，贝塔系数为 2.11。该公司的 50 日简单移动平均线为 5.02 美元，200 日简单移动平均线为 8.14 美元。Olema Pharmaceuticals 的年内最低价为 3.93 美元，最高价为 16.62 美元。</p>
</div><p>Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.51) EPS for the quarter, beating analysts' consensus estimates of ($0.63) by $0.12. As a group, research analysts expect that Olema Pharmaceuticals will post -2.33 earnings per share for the current year.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals（纳斯达克代码：OLMA - 获取免费报告）最近在 3 月 18 日发布了季度财报。该公司报告季度每股收益为（0.51 美元），超出分析师一致预期的（0.63 美元）0.12 美元。整体来看，研究分析师预计 Olema Pharmaceuticals 在当前年度的每股收益将为-2.33 美元。</p>
</div><h2>Insider Activity at Olema Pharmaceuticals</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 内部活动</h2>
</div><p>In related news, major shareholder Bain Capital Life Sciences Inv purchased 300,000 shares of the firm's stock in a transaction dated Wednesday, January 8th. The stock was bought at an average price of $5.76 per share, for a total transaction of $1,728,000.00. Following the purchase, the insider now directly owns 7,800,000 shares in the company, valued at approximately $44,928,000. This trade represents a 4.00 % increase in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. 19.40% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，主要股东 Bain Capital Life Sciences Inv 于 1 月 8 日购买了 30 万股该公司的股票。该股票的平均购买价格为每股 5.76 美元，总交易额为 1,728,000.00 美元。购买后，该内部人士现在直接持有 780 万股公司股票，估值约为 44,928,000 美元。此交易代表其持股比例增加了 4.00%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站访问。19.40% 的股票由内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Olema Pharmaceuticals</h2>
<div class="lb-trans"><h2>对 Olema Pharmaceuticals 的对冲基金看法</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the company. Intech Investment Management LLC purchased a new position in shares of Olema Pharmaceuticals during the 3rd quarter valued at $163,000. Charles Schwab Investment Management Inc. raised its stake in Olema Pharmaceuticals by 168.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 330,761 shares of the company's stock valued at $3,949,000 after acquiring an additional 207,565 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in Olema Pharmaceuticals in the 3rd quarter valued at about $238,000. Portland Investment Counsel Inc. purchased a new stake in Olema Pharmaceuticals during the third quarter valued at about $143,000. Finally, Ikarian Capital LLC bought a new position in Olema Pharmaceuticals during the third quarter worth about $1,098,000. 91.78% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近买卖了该公司的股票。Intech Investment Management LLC 在第三季度购买了 Olema Pharmaceuticals 的新头寸，价值为 163,000 美元。Charles Schwab Investment Management Inc.在第三季度将其在 Olema Pharmaceuticals 的持股比例提高了 168.5%。Charles Schwab Investment Management Inc.现在持有该公司 330,761 股股票，价值为 3,949,000 美元，此前在该期间内又增持了 207,565 股。Dynamic Technology Lab Private Ltd 在第三季度购买了 Olema Pharmaceuticals 的新股份，价值约为 238,000 美元。Portland Investment Counsel Inc.在第三季度购买了 Olema Pharmaceuticals 的新股份，价值约为 143,000 美元。最后，Ikarian Capital LLC 在第三季度购买了 Olema Pharmaceuticals 的新头寸，价值约为 1,098,000 美元。91.78% 的股票由机构投资者持有。</p>
</div><h2>Olema Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于女性癌症治疗的发现、开发和商业化。其主要产品候选药物为 OP-1250，一种雌激素受体（ER）拮抗剂和选择性 ER 降解剂，目前正在进行针对复发性、局部晚期或转移性雌激素受体阳性、HER2 阴性乳腺癌的三期临床试验；同时 OP-1250 与 CDK4/6 抑制剂 palbociclib、ribociclib 和 alpelisib 联合进行一期/二期临床试验，治疗复发性、局部晚期或转移性雌激素受体阳性、HER2 阴性乳腺癌，并开发 OPERA-01 用于 ER+/HER2-晚期或转移性乳腺癌的治疗。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Olema Pharmaceuticals</li>
<li>2 Rising CRM Platform Stocks That Can Surge Higher in 2025</li>
<li>Ibotta Stock: Why the Buyback Looks Like a Bullish Bet</li>
<li>Breakout Stocks: What They Are and How to Identify Them</li>
<li>Joby Aviation Stock: Analyst Confidence and Smart Money Align</li>
<li>How to Invest in Small Cap Stocks</li>
<li>3 Momentum Stocks Near 52-Week Highs to Watch for More Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Olema Pharmaceuticals</li>
<li>2025 年可能大幅上涨的两只 CRM 平台股票</li>
<li>Ibotta 股票：为何回购看起来像是一个看涨的赌注</li>
<li>突破股票：它们是什么以及如何识别它们</li>
<li>Joby Aviation 股票：分析师信心与聪明资金一致</li>
<li>如何投资小型股</li>
<li>3 只接近 52 周高点的动量股，值得关注以获取更多增长</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Olema Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Olema Pharmaceuticals 吗？</h2>
</div><p>Before you consider Olema Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Olema Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Olema Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Olema Pharmaceuticals 并不在名单上。</p>
</div><p>While Olema Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Olema Pharmaceuticals 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

摩根大通将 Olema Pharmaceuticals（NASDAQ:OLMA）的目标价下调至 28.00 美元